Market revenue in 2023 | USD 342.6 million |
Market revenue in 2030 | USD 670.4 million |
Growth rate | 10.1% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 84.44% in 2023. Horizon Databook has segmented the Canada hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
The broadening scope of genetic testing for breast and ovarian cancers is expected to drive the Canadian market. A Canadian National initiative, the Screen Project, launched in March 2017, provided BRCA1 & BRCA2 screening to Canadian population over 18 years of age at an affordable price.
In collaboration with Veritas Genetics, this program offered to monitor population-based genetic testing for breast cancer across Canada. The following diagram represents five specific objectives of the Screen Project.
The Canadian government, through Screen Project, evaluates the feasibility and results of genetic testing for BRCA mutations when offered DTC at a minimum charge. This cost-effective strategy is expected to drive adoption of hereditary testing solutions in Canada.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Canada hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account